ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2308건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2224 | Completed | A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure | SARS CoV-2 Infection | Biological: Human Amniotic Fluid | Early Phase 1 | University of Utah | OTHER | 10 | All | 18 Years | University of Utah Health, Salt Lake City, Utah, United States |
| 2223 | Unknown status | A Pilot Study of Sildenafil in COVID-19 | COVID-19 | Drug: Sildenafil citrate tablets | Phase 3 | Tongji Hospital | OTHER | 10 | All | 18 Years | Department and Institute of Infectious Disease, Wuhan, Hubei, China |
| 2222 | Completed | A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 | Coronavirus Disease 2019 | Drug: Bempegaldesleukin Drug: Standard of Care Other: Placebo |
Phase 1 | Nektar Therapeutics | INDUSTRY | 30 | All | 18 Years | A G A Clinical Trials - HyperCore - PPDS, Hialeah, Florida, United States New Generation Medical Research, Hialeah, Florida, United States Clinical Site Partners - Winter Park - HyperCore -PPDS, Winter Park, Florida, United States SMS Clinical Research, LLC, Mesquite, Texas, United States |
| 2221 | Active, not recruiting | A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in China | SARS-CoV-2 | Biological: COVID-19 Variant (Omicron BA.5) mRNA Vaccine Low dose Biological: COVID-19 Variant (Omicron BA.5) mRNA Vaccine High dose Drug: Placebo |
Not Applicable | AIM Vaccine Co., Ltd., Ningbo Rongan Biological Pharmaceutical Co., Ltd., First Affiliated Hospital Bengbu Medical College | INDUSTRY | 54 | All | 18 Years | First Affiliated Hospital Bengbu Medical College, Bengbu, Anhui, China |
| 2220 | Active, not recruiting | A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5 | COVID-19 Pandemic | Biological: V-01/V-01-B5 Biological: V-01-351/V-01-B5 Biological: V-01 |
Early Phase 1 | Livzon Pharmaceutical Group Inc. | INDUSTRY | 48 | All | 18 Years ~ 59 Years | Shaoguan Hospital of Chinese Medicine, Shaoguan, Guangdong, China |
| 2219 | Completed | A Preventive Treatment for Migrant Workers at High-risk of COVID-19 | Covid-19 | Drug: Hydroxychloroquine Sulfate Tablets Drug: Ivermectin 3mg Tab Drug: Zinc Drug: Povidone-Iodine Dietary Supplement: Vitamin C |
Phase 3 | National University Hospital, Singapore | OTHER | 4257 | Male | 21 Years ~ 60 Years | Tuas South Dormitory, Singapore, Singapore |
| 2218 | Completed | A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients | COVID-19 Pneumonia | Biological: Mesenchymal Stem Cells Transplantation | Not Applicable | SBU Dr. Sadi Konuk E?itim ve Ara?tırma Hastanesi, Istinye University, Liv Hospital (Ulus) | OTHER | 30 | All | 18 Years ~ 65 Years | Istinye University, Istanbul, Turkey SBU Dr. Sadi Konuk E?itim ve Ara?tırma Hastanesi, Istanbul, Turkey |
